HDAC6-IN-10 is a potent and specific HDAC6 inhibitor, exhibiting an IC50 value of 0.73 nM. It demonstrates remarkable selectivity towards HDAC6, with a selectivity range of 144 to 10,941-fold over other HDAC isoforms. Furthermore, HDAC6-IN-10 exhibits notable anti-proliferative effects on multiple myeloma cells [1].

HDAC6-IN-10 (Compound 21b) demonstrates high specificity for inhibiting HDAC6 when administered at 0.1 to 10 μM over 24 hours [1]. At 0 to 100 μM over 72 hours, it exerts anti-proliferative effects on multiple myeloma cell lines RPMI-8226 and U266 [1]. In HCT-116 Western Blot analyses with 0.1, 1, and 10 μM over 24 hours, a dose-dependent increase in Ac-tubulin levels was observed. Cell Proliferation Assays showed inhibition of RPMI-8226 and U266 cell growth, with IC 50 values of 33.183 μM and 43.233 μM, respectively [1].